Abstract | BACKGROUND: METHODS: Data were obtained from the Taiwan's National Health Insurance Research Database. The study enrolled 5,275 PUD or GERD patients, of whom were divided into two groups, based on their exposure (1,055 cases) or non-exposure (4,220 cases) to sulpiride. RESULTS: During the study period (2000-2012), the incidence rate of parkinsonism was 261.5 and 762.2 per 100,000 person-years in the control and sulpiride-treated groups, respectively. For patients with at least 14 days of prescription for sulpiride, the adjusted hazard ratio (aHR) was 2.89, 95% confidence interval (CI): 2.04-4.11. Patients with age more than 65 years (aHR = 4.99, 95% CI = 2.58-9.65), hypertension (aHR = 2.39, 95% CI = 1.49-3.82), depression (aHR = 2.00, 95% CI = 1.38-2.91), and anxiety (aHR = 1.45, 95% CI = 1.01-2.09) had significant higher risk of developing parkinsonism. An average annual cumulative sulpiride dose > 1,103 mg was accompanied by the greatest risk of SIP; sulpiride use for ≥ 9 days is a cut-off point for predicting future SIP. CONCLUSION: At the population level, sulpiride may be frequently prescribed and apparently effective for PUD and GERD. SIP is associated with older age, hypertension, depression or anxiety comorbidities. Physicians should be aware of the neurogenic adverse effects, even when the drug is only used in low-dose or a short duration.
|
Authors | Cheng-Yu Wei, I-Shiang Tzeng, Mei-Chen Lin, Yung-Hsiang Yeh, Chung Y Hsu, Woon-Man Kung |
Journal | Frontiers in pharmacology
(Front Pharmacol)
Vol. 11
Pg. 433
( 2020)
ISSN: 1663-9812 [Print] Switzerland |
PMID | 32390831
(Publication Type: Journal Article)
|
Copyright | Copyright © 2020 Wei, Tzeng, Lin, Yeh, Hsu and Kung. |